Measurement of serum CA 19-9 may be more valuable than CEA in prediction of recurrence in patients with gastric cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 2, 2001, Pages 148-149

  Tas, Faruk ^a   Faruk Aykan, N ^a   Aydiner, Adnan ^a   Yasasever, Vildan ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

CA 19 9; CEA; Gastric cancer; Recurrence

Indexed keywords

CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; GASTRECTOMY; HUMAN; STOMACH CANCER;

CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GASTRECTOMY; HUMANS; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS;

EID: 0035045196     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200104000-00010     Document Type: Article

References (8)

1. Gastric cancer
2. The value of CA 19-9 in gastric and colorectal carcinoma
3. Significance of CA 72-4 as a follow up of recurrent gastric cancer - Comparison with CEA and CA 19-9
4. Comparison of CA 724, CA 19-9 and CEA in the diagnosis and monitoring of gastric cancer
5. CEA, CA 19-9, and CA 50 in monitoring gastric carcinoma
6. Stomach adenocarcinomas: Comparison between CA 19.9 and carcinoembryonic antigen for the diagnosis of recurrences after surgical treatment
7. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies
8. The clinical efficacy of CA 72-4 as serum marker for gastric cancer in comparison with CA19-9 and CEA